AnaptysBio reports Phase IIa data for peanut allergy candidate

AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial showing that six of 13 (46%) patients exhibiting moderate to severe peanut allergy symptoms during

Read the full 260 word article

User Sign In